| ID Source | ID |
|---|---|
| PubMed CID | 891086 |
| CHEMBL ID | 1426282 |
| CHEBI ID | 107471 |
| SCHEMBL ID | 5435379 |
| Synonym |
|---|
| HMS1686O09 |
| 5-benzyl-4-[(furan-2-yl)methyl]-4h-1,2,4-triazole-3-thiol |
| 537017-46-2 |
| EN300-26408 |
| REGID_FOR_CID_891086 |
| OPREA1_531876 |
| smr000072751 |
| 5-benzyl-4-(2-furylmethyl)-2,4-dihydro-3h-1,2,4-triazole-3-thione |
| MLS000088730 , |
| CHEBI:107471 |
| AKOS000569559 |
| 3-benzyl-4-(furan-2-ylmethyl)-1h-1,2,4-triazole-5-thione |
| HMS2456N24 |
| 5-benzyl-4-(2-furylmethyl)-4h-1,2,4-triazole-3-thiol |
| AB00764626-01 |
| 5-benzyl-4-(furan-2-ylmethyl)-4h-1,2,4-triazole-3-thiol |
| SCHEMBL5435379 |
| AKOS016882346 |
| 3-benzyl-4-(2-furfuryl)-1h-1,2,4-triazole-5-thione |
| bdbm42381 |
| cid_891086 |
| 4-(furan-2-ylmethyl)-3-(phenylmethyl)-1h-1,2,4-triazole-5-thione |
| 4-(2-furanylmethyl)-3-(phenylmethyl)-1h-1,2,4-triazole-5-thione |
| CHEMBL1426282 |
| Q27185788 |
| BRD-K71276538-001-08-9 |
| 5-benzyl-4-furan-2-ylmethyl-4h-[1,2,4]triazole-3-thiol |
| Z58287194 |
| Class | Description |
|---|---|
| benzenes | Any benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 31.6228 | 0.0251 | 20.2376 | 39.8107 | AID893 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 31.6228 | 0.0251 | 20.2376 | 39.8107 | AID893 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 3.9811 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 0.1836 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
| hypothetical protein, conserved | Trypanosoma brucei | Potency | 31.6228 | 0.2239 | 11.2451 | 35.4813 | AID624173 |
| IDH1 | Homo sapiens (human) | Potency | 35.4813 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 29.0929 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 79.4328 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 13.3573 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
| lethal(3)malignant brain tumor-like protein 1 isoform I | Homo sapiens (human) | Potency | 6.3096 | 0.0752 | 15.2253 | 39.8107 | AID485360 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| short transient receptor potential channel 6 isoform 1 | Mus musculus (house mouse) | EC50 (µMol) | 39.8100 | 0.0200 | 20.5189 | 70.7900 | AID2696 |
| Lysosomal acid glucosylceramidase | Homo sapiens (human) | EC50 (µMol) | 50.0000 | 2.5000 | 2.5000 | 2.5000 | AID1268 |
| Amine oxidase [flavin-containing] B | Rattus norvegicus (Norway rat) | EC50 (µMol) | 50.0000 | 0.3300 | 1.2650 | 2.2000 | AID1268 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| galactosylceramidase activity | Lysosomal acid glucosylceramidase | Homo sapiens (human) |
| glucosylceramidase activity | Lysosomal acid glucosylceramidase | Homo sapiens (human) |
| signaling receptor binding | Lysosomal acid glucosylceramidase | Homo sapiens (human) |
| scavenger receptor binding | Lysosomal acid glucosylceramidase | Homo sapiens (human) |
| protein binding | Lysosomal acid glucosylceramidase | Homo sapiens (human) |
| glucosyltransferase activity | Lysosomal acid glucosylceramidase | Homo sapiens (human) |
| steryl-beta-glucosidase activity | Lysosomal acid glucosylceramidase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| lysosome | Lysosomal acid glucosylceramidase | Homo sapiens (human) |
| lysosomal membrane | Lysosomal acid glucosylceramidase | Homo sapiens (human) |
| endoplasmic reticulum | Lysosomal acid glucosylceramidase | Homo sapiens (human) |
| Golgi apparatus | Lysosomal acid glucosylceramidase | Homo sapiens (human) |
| trans-Golgi network | Lysosomal acid glucosylceramidase | Homo sapiens (human) |
| lysosomal lumen | Lysosomal acid glucosylceramidase | Homo sapiens (human) |
| extracellular exosome | Lysosomal acid glucosylceramidase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.20) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||